Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

57
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
57
Cross-reactivity00:42

Cross-reactivity

33.8K
Overview
33.8K
Vaccines01:21

Vaccines

42
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
42

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant human diamine oxidase prevents histamine-induced hypoxia, shock and death in guinea pigs.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis.

Drug discovery today·2026
Same author

Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: an updated meta-analysis.

Scientific reports·2026
Same author

Effects of an early restrictive versus liberal fluid strategy on long-term patient-centered outcomes in sepsis-induced hypotension: an open-label, randomized controlled trial.

American journal of respiratory and critical care medicine·2026
Same author

Abnormal whole-blood viscoelastic test results in patients with bleeding disorder of unknown cause.

Blood vessels, thrombosis & hemostasis·2026
Same author

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

American journal of hematology·2026
Same journal

Vaccination practice and safety in children with special health care needs: A retrospective study of 1278 children.

Human vaccines & immunotherapeutics·2026
Same journal

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.

Human vaccines & immunotherapeutics·2026
Same journal

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Human vaccines & immunotherapeutics·2026
Same journal

Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Human vaccines & immunotherapeutics·2026
Same journal

Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.

Human vaccines & immunotherapeutics·2026
Same journal

Determinants of HPV vaccination acceptance among young adult women in Japan's catch-up generation: A cross-sectional study.

Human vaccines & immunotherapeutics·2026
See all related articles

Related Experiment Video

Updated: Mar 30, 2026

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

15.0K

Chikungunya vaccines in development.

Michael Schwameis1, Nina Buchtele1, Patricia Pia Wadowski1

  • 1a Departments of Clinical Pharmacology and Internal Medicine I , Medical University of Vienna , Vienna , Austria.

Human Vaccines & Immunotherapeutics
|November 12, 2015
PubMed
Summary
This summary is machine-generated.

Developing a chikungunya virus vaccine is crucial as the virus spreads globally with no available treatments. Current research highlights promising vaccine candidates progressing to clinical trials.

Keywords:
Chikungunyaclinical trialslive virus vaccinemeasles virusreviewvirus-like particles

More Related Videos

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

8.6K
A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses
05:22

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses

Published on: November 4, 2025

798

Related Experiment Videos

Last Updated: Mar 30, 2026

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

15.0K
Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice
10:01

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

8.6K
A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses
05:22

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses

Published on: November 4, 2025

798

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Chikungunya virus (CHIKV) poses a significant global health threat, expanding into Europe and the Americas.
  • No specific antiviral treatments or prophylactic vaccines are currently available for chikungunya infection.
  • Vaccine development efforts for CHIKV have been ongoing since the late 1960s, exploring diverse strategies.

Purpose of the Study:

  • To review the current status of human vaccine development against chikungunya virus.
  • To discuss various immunization strategies employed for CHIKV.
  • To highlight recent clinical trial outcomes and promising vaccine candidates.

Main Methods:

  • Review of scientific literature on chikungunya vaccine development.
  • Analysis of immunization strategies and vaccine platforms.
  • Examination of data from recent human clinical trials.

Main Results:

  • Two chikungunya vaccine candidates have advanced to Phase II clinical trials: a virus-like particle-based vaccine and a recombinant measles virus-vectored vaccine.
  • Various immunization strategies have been explored, indicating progress in the field.
  • Recent human trials provide insights into the safety and immunogenicity of candidate vaccines.

Conclusions:

  • Significant progress has been made in chikungunya vaccine development, with promising candidates entering advanced clinical trials.
  • The diversity of approaches underscores the complexity and importance of finding an effective CHIKV vaccine.
  • Continued research and clinical evaluation are essential to combat the global threat of chikungunya virus.